MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 10-28-2024
Inari Medical Total Assets 2011-2026 | NARI
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Inari Medical
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 504 M | 312 M | 214 M | 44.5 M | 26.9 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 504 M | 26.9 M | 220 M |
Quarterly Total Assets Inari Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 697 M | 673 M | 662 M | 674 M | 549 M | 525 M | 507 M | 504 M | 488 M | - | 484 M | 312 M | 292 M | 254 M | 235 M | 214 M | 214 M | 214 M | 214 M | 44.5 M | 44.5 M | 44.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 697 M | 44.5 M | 374 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apyx Medical Corporation
APYX
|
66.8 M | $ 3.72 | 0.95 % | $ 153 M |  USA |
 |
AxoGen
AXGN
|
222 M | $ 33.03 | -4.08 % | $ 1.52 B | USA |
 |
Butterfly Network
BFLY
|
256 M | $ 4.07 | -1.09 % | $ 862 M | USA |
 |
AdaptHealth Corp.
AHCO
|
4.32 B | $ 12.25 | 1.79 % | $ 1.66 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 36.66 | -0.27 % | $ 5.46 K | USA |
 |
Boston Scientific Corporation
BSX
|
43.7 B | $ 62.57 | -0.4 % | $ 92.6 B | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
ClearPoint Neuro
CLPT
|
97.7 M | $ 9.41 | 0.48 % | $ 266 M | USA |
 |
CONMED Corporation
CNMD
|
2.33 B | $ 34.54 | -0.72 % | $ 1.07 B | USA |
 |
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.62 | 5.64 % | $ 38.6 M | USA |
 |
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | USA |
 |
Delcath Systems
DCTH
|
124 M | $ 9.76 | 1.35 % | $ 350 M | USA |
 |
EDAP TMS S.A.
EDAP
|
91.5 M | $ 3.5 | 3.24 % | $ 131 M |  France |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 81.26 | 0.26 % | $ 47.5 B | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.6 | 0.04 % | $ 122 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Align Technology
ALGN
|
6.21 B | $ 170.52 | -0.05 % | $ 12.8 B | USA |
 |
Helius Medical Technologies
HSDT
|
7.69 M | $ 1.87 | 0.27 % | $ 1.14 M | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 9.31 | -2.31 % | $ 717 M | USA |
 |
Inogen
INGN
|
299 M | $ 6.42 | 3.38 % | $ 171 M | USA |
 |
IRIDEX Corporation
IRIX
|
29.2 M | $ 0.99 | 1.47 % | $ 16.8 M | USA |
 |
IRadimed Corporation
IRMD
|
109 M | $ 96.6 | 0.38 % | $ 1.23 B | USA |
 |
Integer Holdings Corporation
ITGR
|
3.41 B | $ 85.01 | -2.12 % | $ 2.95 B | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
OrthoPediatrics Corp.
KIDS
|
509 M | $ 15.95 | -0.68 % | $ 374 M | USA |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
LENSAR
LNSR
|
71.4 M | $ 5.97 | -1.49 % | $ 71.4 M | USA |
 |
Pulmonx Corporation
LUNG
|
129 M | $ 1.38 | 3.38 % | $ 56.1 M | USA |
 |
Medtronic PLC
MDT
|
91.7 B | $ 86.52 | -0.13 % | $ 111 B | USA |
 |
MiMedx Group
MDXG
|
343 M | $ 3.89 | -0.89 % | $ 575 M | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Myomo
MYO
|
38.6 M | $ 0.69 | 3.22 % | $ 28.9 M | USA |